Life Science Nation Newsletter | December 6, 2018 | Issue 295

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
RESI San Francisco 2019
   Life Science Investor Mandates
(Nov. 29 - Dec. 5 )
Seeks to Invest Primarily in Breakthrough Oncology Therapeutics
Invests in Therapeutics, Devices, Diagnostics, and Digital Health Companies in Taiwan and North America
Invests in Novel Oncology Therapeutics, Diagnostics, and Devices, Including Rare Cancers
Invests in Early-Stage Therapeutics, Medtech, and Digital Health Companies with Clearly Established Developmental Pathways
LSN Services
LSN Videos
LSN Media Partners
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

San Francisco's annual healthcare conference week starts in just over a month. Already, hundreds of investors have signed up to attend RESI San Francisco - our largest event of the year, which serves as a dedicated venue for early stage investors to meet with startups in the biotech, medical device, diagnostic and digital health sectors. While many of these investors cover multiple silos in their hunt for the most promising opportunities, we have highlighted some top investors in each of RESI's core innovation sectors below. Would you like to book up to 16 face-to-face meetings with investors on January 8th? Register online to join us at RESI...

Confirmed Therapeutics Investors

Confirmed Medical Devices Investors

Confirmed Diagnostics Investors

Confirmed Digital Health Investors

By Claire Jeong, Senior Research Analyst, LSN

There are several important dates related to RESI San Francisco 2019 this week. With yesterday's RESI partnering system launch, there is no doubt that our largest event of the year is closely approaching. Another date to keep in mind is tomorrow, Friday, December 7th, as Friday is the last date we are accepting applications for the RESI SF Innovation Challenge.

As usual, we will be selecting 30 finalists who are working on innovative technologies with high potential to scale in global markets. The Innovation Challenge is open to all early-stage companies in the therapeutics, medical devices, diagnostics, and digital health sectors who are actively fundraising. We will also be selecting several tech hub constituents to participate in the West Coast Innovators' Pitch Challenge from 1:00 - 2:30 pm, where companies will be able to pitch in front of a panel of established investor judges and receive constructive feedback...

By Lucy Parkinson, VP of Investor Research, LSN

Artificial intelligence is widely seen as the new frontier of tech innovation, and many applications for the technology have been found in healthcare. Scientist-entrepreneurs are exploring AI diagnostics, AI drug discovery, AI imaging analysis, AI for personalized medicine, and more. At RESI San Francisco, a panel of investors who focus on this field will discuss how they see the risks and opportunities that are arising for AI in healthcare. The panelists are:
  • Elaine Mo, Ascend Capital Partners
  • Edward Kliphuis, M Ventures
  • Armen Vidian, Data Collective
  • Lu Zhang, Fusion Fund
  • Yizhen Dong,11.2 Capital
Panelists will discuss what they're looking for when they evaluate an AI opportunity, what challenges (including regulatory) they see on the horizon, and where they see the real potential for AI technologies in health. Join us at RESI to see this panel live...

Created & Produced by